Evidence map›Paper›PMID 37286545›Full record

ArticleBlood cancer journal2023

Integrated multi-omics analyses reveal homology-directed repair pathway as a unique dependency in near-haploid leukemia.

Yunpeng Liu-Lupo, James Dongjoo Ham, Swarna K A Jeewajee, Lan Nguyen, Toni Delorey, Azucena Ramos, David M Weinstock, Aviv Regev, Michael T Hemann

Open access · goldAbstract read
In one paragraph

Article in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yunpeng Liu-Lupo *Department of Biology, Massachusetts Institute of Technology, Cambridge, USA.
James Dongjoo Ham *Department of Biology, Massachusetts Institute of Technology, Cambridge, USA.ORCID 0000-0003-0971-7940
Swarna K A JeewajeeDepartment of Biology, Massachusetts Institute of Technology, Cambridge, USA.ORCID 0000-0002-0531-9980
Lan NguyenBroad Institute of MIT and Harvard, Cambridge, USA.
Toni DeloreyBroad Institute of MIT and Harvard, Cambridge, USA.ORCID 0000-0001-6614-3803
Azucena RamosDepartment of Biology, Massachusetts Institute of Technology, Cambridge, USA.
David M WeinstockBroad Institute of MIT and Harvard, Cambridge, USA.
Aviv RegevDepartment of Biology, Massachusetts Institute of Technology, Cambridge, USA.ORCID 0000-0003-3293-3158
Michael T HemannDepartment of Biology, Massachusetts Institute of Technology, Cambridge, USA. hemann@mit.edu.ORCID 0000-0001-6776-2163
Broad Institute · USAllen Institute · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Targeting High-Risk Lymphoid NeoplasmsR35CA231958 · NCI · DANA-FARBER CANCER INST · PI WEINSTOCK, DAVID MARC · 2019 to 2021
$2.9M
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer TherapiesR01CA226898 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B, HEMANN, MICHAEL · 2019 to 2023
$2.7M
Identifying and targeting evolutionary trajectories in cancerR01CA233477 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HEMANN, MICHAEL · 2019 to 2023
$1.7M
Dissecting the mechanism of cyclophosphamide-enhanced antibody efficacyR21AI151827 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HEMANN, MICHAEL · 2020 to 2021
$408k
Howard Hughes Medical InstituteNCI NIH HHS P30 CA014051NCI NIH HHS R01 CA226898NCI NIH HHS R01 CA233477NCI NIH HHS R35 CA231958NIAID NIH HHS R21 AI151827NIGMS NIH HHS T32 GM007753
6 · The paper itself

Abstract

Whole chromosome losses resulting in near-haploid karyotypes are found in a rare subgroup of treatment-refractory acute lymphoblastic leukemia. To systematically dissect the unique physiology and uncover susceptibilities that can be exploited in near-haploid leukemia, we leveraged single-cell RNA-Seq and computational inference of cell cycle stages to pinpoint key differences between near-haploid and diploid leukemia cells. Combining cell cycle stage-specific differential expression with gene essentiality scores from a genome-wide CRISPR-Cas9-mediated knockout screen, we identified the homologous recombination pathway component RAD51B as an essential gene in near-haploid leukemia. DNA damage analyses revealed significantly increased sensitivity of RAD51-mediated repair to RAD51B loss in the G2/M stage of near-haploid cells, suggesting a unique role of RAD51B in the homologous recombination pathway. Elevated G2/M and G1/S checkpoint signaling was part of a RAD51B signature expression program in response to chemotherapy in a xenograft model of human near-haploid B-ALL, and RAD51B and its associated programs were overexpressed in a large panel of near-haploid B-ALL patients. These data highlight a unique genetic dependency on DNA repair machinery in near-haploid leukemia and demarcate RAD51B as a promising candidate for targeted therapy in this treatment-resistant disease.

Indexed as

Leukemia, LymphoidMultiomicsChromosome AberrationsDNA RepairHaploidyHumansProteinsProteins

Identifiers

PMID37286545
PMCPMC10247733
OpenAlexW4379739936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.